The elevation of PD-L1 following CHK1 targeting was additionally validated by subjecting cells to a second CHK1 inhibitor, LY2603618 (also known as Rabusertib, manufactured by Eli Lilly and Company, Indianapolis, IN, United States), in SCLC cell lines [77]. The gene discussed is CD274; the disease is small cell lung carcinoma.